Cited 7 time in
Cited 6 time in
Application of elastin-mimetic recombinant proteins in chemotherapeutics delivery, cellular engineering, and regenerative medicine
- Application of elastin-mimetic recombinant proteins in chemotherapeutics delivery, cellular engineering, and regenerative medicine
- Jeon, Won Bae
- DGIST Authors
- Jeon, Won Bae
- Issue Date
- Bioengineered, 4(6), 368-373
- Article Type
- Article; Note
- Animal; Animals; Bio-Compatible Materials; Biomaterial; Biomimetics; Biopolymer; Biopolymers; Cell Engineering; Chemistry; Drug and Gene Delivery; Drug Delivery System; Drug Delivery Systems; Elastin; Elastin-Like Proteins; Extracellular Matrix; Gene Transfer; Gene Transfer Techniques; Genetic Engineering; Human; Humans; Hydrogel; Hydrogels; Methodology; Recombinant Protein; Recombinant Proteins; Regenerative Medicine; Surface-Coatings
- With the remarkable increase in the fields of biomedical engineering and regenerative medicine, biomate-rial design has become an indispensable approach for developing the biocompat-ible carriers for drug or gene cargo and extracellular matrix (ECM) for cell survival, proliferation and differentiation. Native ECM materials derived from animal tissues were believed to be the best choices for tissue engineering. However, possible pathogen contamination by cellular remnants from foreign animal tissues is an unavoidable issue that has limited the use of native ECM for human benefit. Some synthetic polymers have been used as alternative materials for manufacturing native ECM because of the biodegradability and ease of large-scale production of the polymers. However, the inherent polydispersity of the polymers causes batch-to-batch variation in polymer composition and possible cytotoxic interactions between chemical matrices and neighboring cells or tissues have not yet been fully resolved. Elastin-like proteins (ELPs) are genetically engineered biopolymers modeled after the naturally occurring tropoelastin and have emerged as promising materials for biomedical applications because they are biocompatible, non-immunogenic and biodegradable, and their composition, mechanical stiffness and even fate within the cell can be controlled at the gene level. This commentary highlights the recent progresses in the development of the ELP-based recombinant proteins that are being increasingly used for the delivery of chemotherapeutics and to provide a cell-friendly ECM environment. © 2013 Landes Bioscience.
- LANDES BIOSCIENCE
- Related Researcher
There are no files associated with this item.
- Companion Diagnostics and Medical Technology Research Group1. Journal Articles
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.